UNSPSC 51123006: Lorajmine

This classification denotes an anti-arrhythmia agent with the molecular formula C22H27ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) F96VX65849, chemically known as ajmalan-17,21-diol, 17-(chloroacetate) but more generally known as lorajmine, which bears US NIH Compound Identifier 92090. European Medicines Agency schedules Lorajmine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08579MIG.

UNSPSC 51123006 Lorajmine, a Commodity code, addresses injectable cardiac and hemodynamic medications used by emergency medical services and hospital systems. State and local governments procure lorajmine and related advanced life support drugs for fire departments, emergency medical services agencies, and health systems serving municipal and county populations. The solicitations involve sealed competitive bidding for specific medication line items, typically as part of broader Advanced Life Support pharmaceutical packages, with vendors required to meet FDA compliance, cGMP standards, expiration-date warranties, and OSHA hazard communication documentation. Issuing bodies include city purchasing departments, state health agencies, and regional cooperative purchasing alliances serving multi-state membership. The City of Tampa, Texas Health and Human Services Commission, and Minnesota's cooperative purchasing alliance have all issued solicitations in this category recently, reflecting activity across municipal fire and rescue operations, state pharmacy benefit programs, and multi-jurisdictional bulk pharmaceutical procurement.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB for Advanced Life Support Medications (Bid No. 26-P-00188) in April 2026 with a $40,000 estimated contract value and April 8, 2026 response deadline, requiring 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with a one-year term and optional two-year renewals; the procurement includes a 5 percent bid discount for Small Local Business Enterprise participation, not to exceed $10,000. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer pharmacy contracting models outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and a 3 percent administrative fee structure weighted 75 percent on price competitiveness. State and local pharmaceutical procurement in this category emphasizes immediate delivery requirements, expiration-date compliance, wholesaler certification, and competitive pricing models under cooperative purchasing arrangements.